3 Results Found

Advanced Search

Select all

Results per page

Select all

Review

23 Citations

8,470 Views

14 Pages

Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers

Tyler E. Mattox,
Xi Chen,
Yulia Y. Maxuitenko,
Adam B. Keeton and
Gary A. Piazza

Int. J. Mol. Sci.2020, 21(1), 141;https://doi.org/10.3390/ijms21010141

-

24 December 2019

Oncogenic mutations in RAS genes result in the elevation of cellular active RAS protein levels and increased signal propagation through downstream pathways that drive tumor cell proliferation and survival. These gain-of-function mutations drive over...

Full Article

Article

5 Citations

4,078 Views

15 Pages

A Membrane Permeable Prodrug of S223 for Selective Epac2 Activation in Living Cells

Yunjian Xu,
Frank Schwede,
Hans Wienk,
Anders Tengholm and
Holger Rehmann

Cells2019, 8(12), 1589;https://doi.org/10.3390/cells8121589

-

6 December 2019

Signalling by cyclic adenosine monophosphate (cAMP) occurs via various effector proteins, notably protein kinase A and the guanine nucleotide exchange factors Epac1 and Epac2. These proteins are activated by cAMP binding to conserved cyclic nucleotid...

Full Article

Article

6 Citations

3,968 Views

20 Pages

Comparative Analysis of the GNAI Family Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies

Ahmad Raza,
Meng-Chi Yen,
Gangga Anuraga,
Iram Shahzadi,
Muhammad Waqar Mazhar,
Hoang Dang Khoa Ta,
Do Thi Minh Xuan,
Sanskriti Dey,
Sachin Kumar and
Chih-Yang Wang
+ 2 authors

Cancers2023, 15(20), 5112;https://doi.org/10.3390/cancers15205112

-

23 October 2023

Glioblastoma multiforme (GBM) is one of the most aggressive cancers with a low overall survival rate. The treatment of GBM is challenging due to the presence of the blood–brain barrier (BBB), which hinders drug delivery. Invasive procedures alo...

Full Article